Document:

Exhibit 10.13

 

INTELLECTUAL PROPERTY ASSIGNMENT

 

This Intellectual Property Assignment (the “Assignment”)
is made 5 December 2012 (the “Effective Date”), by Jeffrey A. Carlisle, and individual residing at 103
Winnicutt Road, Stratham, New Hampshire 03885-2462 (“Assignor”) to Leveraged Developments LLC, a New Hampshire
limited liability company, having its principal place of business at 103 Winnicutt Road, Stratham, New Hampshire 03885-2462 (“Assignee”
or the “Company”).

 

BACKGROUND

 

		A.	Assignor is in the process
of developing a fluid infusion module for an improved enteral feeding device, as more particularly described on the attached Exhibit
A (the “Development”).

 

		B.	Assignor owns one hundred
percent (100%) of the membership interest of the Company.

 

		C.	Assignor desires to assign and Assignee desires to accept
and assume, all of Assignor’s rights in the Development to the Company.

 

NOW, THEREFORE,
in consideration of $10.00, and the mutual covenants and promises herein contained, and other good and valuable consideration,
the receipt and adequacy of which is hereby acknowledged, the parties agree as follows:

 

1.            ASSIGNMENT

 

1.1           Assignor hereby assigns
and agrees to assign unto Assignee the full and exclusive right, title, and interest in and to the Development, in any form or
embodiment, in the United States and in all foreign countries, including without limitation, all rights in inventions, patents,
patent applications, data, works, discoveries, designs, technology, trade secrets, know how, trademarks and trade dress rights
(including any the goodwill associated with the trademarks and trade dress), copyrights, improvements, embodied in or related to
the Development, whether or not registrable or patentable (hereinafter, the “Intellectual Property Rights”), which
shall become the sole and exclusive property of Assignee.

 

1.2           Assignor
agrees to cooperate fully with Assignee and its representatives in connection with the Development and improvements thereto, including
full disclosure thereof and preparation and filing of any patent applications, and to execute all papers which Assignee, its successors
and assigns, may in their sole discretion and expense deem necessary or desirable. Assignor hereby agree to communicate to Assignee
or its representatives any facts known to Assignor respecting the Development and improvements, to testify in any legal proceedings
relating thereto, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue, and re-examination
applications, make all rightful oaths and declarations, and, in addition, to execute any and all documents that may be required
in order that Assignee may make applications in its own name for patents on the Development and improvements thereon in the United
States and all foreign countries.

 

    	 	1	 

     

    

  

2.            GENERAL
PROVISIONS

 

3.1           This
Assignment constitutes the entire agreement and understanding of the parties with
regard to the subject matter hereof and merges and supersedes all prior discussions, negotiations, understandings and agreements
between the parties concerning the subject matter hereof. No modifications, additions, or amendments to this Assignment shall be
effective unless made in writing and executed by a duly authorized representative of each party.

 

3.2           This
Assignment shall be governed in all respects by the laws of the United States of America and by the laws of the State of New Hampshire,
both as to interpretation and performance, regardless of the choice of law rules of that or any other state or jurisdiction.

 

3.3           Except
as expressly stated herein, nothing in this Assignment is intended to confer benefits, rights, or remedies unto any person or entity
other than the parties hereto or their successors and assigns. Assignee may assign this Assignment without the prior consent of
Assignor. Assignor may not assign this Assignment with the consent of Assignee and any such attempted assignment shall be void.
Subject to the restrictions on assignment and transfer herein, this Assignment shall inure to the benefit of and be binding upon
the parties hereto and their respective successors and assigns.

 

IN WITNESS WHEREOF, the parties have executed
this Assignment as of the Effective Date.

 

	ASSIGNOR:	 	ASSIGNEE:
	 	 	 
	 	 	LEVERAGED  DEVELOPMENTS LLC
	 	 	 
	/s/ Jeffey Carlisle	 	By:	/s/ Jeffey Carlisle, Member
	 Jeffey Carlisle	 	 	 

 

    	 	2	 

     

    

 

EXHIBIT A

 

1ntellectual property

 

Prepared by: Jeffrey Carlisle

Founder,
Leveraged Developments

1/9/2012

Revised 10/20/2012

 

Unique lntellectual Property

 

The following characteristics of a
fluid infusion module are thought to be inventive. The key inventions are printed in bold. The company will seek patent protection
on most or all of the elements below and will, in the meantime, operate under a confidential disclosure agreement with all outside
parties.

 

The inventions have been conceived
during a design process for an improved enteral feeding device, which imposes very high standards for usability and economy. Each
invention will almost certainly have utility beyond enter the feeding application. Each patent, when filed, will be constructed
to broaden the use, where appropriate, to other fluid moving applications beyond the scope of enteral feeding, such as IV therapy.

 

		1.	“Active Air Elimination”: The use of negative pressure to extract air from a fluid source through a hydrophobic membrane
and a check valve.

 

		a.	Traditionally, air leaves the system through an AEF with positive fluid pressure with respect to atmosphere. This requires
a constraint of positive source pressure.

 

		b.	This concept applies a negative pressure with respect to atmosphere to the filter, actively withdrawing air from the system
without the constraint of positive source pressure. The removal of a constraint is, by itself, a benefit.

 

		c.	This concept does not require any diversion of fluid, using valves or the like, nor does it require an air detection means.
It operates intrinsically with a series of configuration of a partial vacuum, a checkvalve, hydrophobic filter material, and the
fluid source, comprised of a mixture of liquid and gas.

 

		2.	“Pneumatically Coupled Direct Drive”: A pneumatically coupled direct drive mechanism.

 

		a.	Traditionally, pumps have used powerful mechanical means to deform tubing or move syringes to compel fluid flow from within
these structures. This direct drive mechanism has the advantage of a very simple control algorithm in which a drive motor is advanced
in known increments with a known stroke volume. Faster flow rates have shorter intervals between motor pulses. Traditional direct
drive architectures diminish the sensitivity to the underlying fluid flow going to the patient and potentially exposes the patient
to high pumping pressures.

 

    	 	3	 

     

    

  

		b.	This invention takes the advantage of a simple direct drive mechanism yet offers the ability to measure the fluid flow outcome
and have increased sensitivity to the environmental factors. This concept applies relatively low pressures, similar to those seen
with a gravity infusion, to the fluid and the observation of fluid flow can be observed directly. A thin non-permeable membrane
separates the driving air pressure from the fluid being delivered and the net force on the membrane approaches zero. The membrane
is formed, like a loudspeaker, in a way where no stretching forces are seen by the membrane; it
translates freely on one axis in response to any changes in differential pressure.

 

		i.	A precision air piston is moved via a stepper motor and a precision leadscrew. The precision from each of the components is
inherent in the manufacturing process and does not add cost to the system design. Just like a direct drive pump, the motor is advanced
at an interval which equals the targeted flow rate.

 

		ii.	Any reference to a piston may also refer to an array of
pistons, connected to a single drive motor. Various linear or rotary configurations of pistons can be used to meet packaging requirements,
but the fundamental relationship between a known activation of a stepper motor and a known change in piston air volume is retained.

 

		iii.	Any reference to a stepper motor could be replaced by any other type of motor and an appropriate encoder that measures its
actual displacement.

 

		iv.	Each step of the motor provides a known and constant change in air volume in the system. The resultant change in absolute pressure
provides a measurement of the total gas volume. So, each step of the motor gives an indication of the in fluid volume at any point
in time. Changes in fluid volume over time provides an indication for flow rate.

 

		v.	When the air piston is advanced, the pressure driving the fluid increases and then decreases as fluid leaves the system and
“leaks” into the patient. The change in pressure provides a realtime proportional signal related to fluid flow rate
..

 

		vi.	Each step provides a new measurement of fluid volume and each measurement in between steps provides a change in pressure proportional
to fluid flow. In this way, a single measurement system is used in two ways to measure flow rate.

 

    	 	4	 

     

    

  

		vii.	At very low flow rates, the pressure changes are small and eventually run into a signal to noise issue. This noise includes
environmental changes of temperature and atmospheric pressure. If
the single movement of the air piston results in a pressure greater than desired, then an alternative strategy can be employed
to measure air volume. Rather than advance the air piston, the air piston can be withdrawn several steps and then returned to the
original position, resulting on no net pressure increase. This “net zero” perturbation of air volume can be large enough
to provide a large signal, well above the noise floor.

 

		3.	“Filter Based Pump Membrane”: The use of a hydrophobic filter material as a pumping membrane.

 

		a	Traditionally, Air Eliminating Filters have been used to supplement a pumping system. The positive contributions of the AEF
are obvious, namely, the filtration of fluid for particulates and the elimination of unwanted air bubbles. An AEF, however, also
introduces negative performance characteristics, such as unwanted compliance in the system and added cost.

 

		b.	This concept of using the AEF as the pumping chamber

 

		i.	exploits the compliance or capacitance of the chamber and puts it to good use, providing the stroke volume needed for a pump

 

		11.	uses the AEF component as the pump, virtually removing it’s incremental cost

 

		4.	“Self-Regulating Flow Control”: A self-regulating fluid flow control strategy.

 

		a.	Traditionally, the creation of a closed loop control system might require a sophisticated and complex
control system. This complexity could lead to problems with reliability and with excessive power consumption.

 

		b.	This architecture allows for the benefits of a timer-based open loop pumping system (simplicity) and the benefits of a closed
loop control system (accuracy and responsiveness).

 

		i.	Since the system accurately measures liquid volume delivered to the patient and accurately measures time, then it is easy to
measure the amount due the patient at any instant in time.

 

		ii.	Following every FILL cycle of the fluid chamber, the calculation is made on the time desired
to empty the chamber. The time between steps is calculated internally. If,for
example, the nominal flow rate is 2 mL to
be delivered over 60 seconds and the pump starts this cycle in debt to the patient of 0.2 mL, then the normal 2.0 mL cycle should
be shortened by approximately I 0% or should be completed in 54 seconds. Since the number of steps required to displace
2.0 mL is precisely known, the time between steps is easily determined.

 

    	 	5	 

     

    

  

		iii.	Following a FILL cycle, there is no flow out to the patient until the outlet valve cracking pressure has been met. The calculations
of timing are made at the moment that the outlet valve cracking pressure is met following a FILL. This method intrinsically accounts
for the intra-cycle delays with no need for complex control calculation.

 

		1v.	At the end of an EMPTY cycle, there is sustained flow out to the patient until the driving pressure falls below the outlet
valve cracking pressure. The FILL cycle is delayed until this point in the pressure decay. This method intrinsically accounts for
the intra cycle delays with no need for complex control calculation.

 

		v.	If the pump is running behind in its rate, then the steps will
happen more rapidly and the delivery pressure will intrinsically increase, causing the rate to catch up to the desired rate. This
requires no control code at all to make this pressure adjustment.

 

		vi.	If the pump
is running ahead in its rate, then the steps will happen
less rapidly and the delivery pressure will intrinsically decrease, causing the rate to slow down to the desired rate. This requires
no control code at all to make this pressure adjustment.

 

		5.	“Mechanical Lock”: The use of a mechanical lock to retain the admin set within the pump, unless purposefully unlock
under program control.

 

		a.	Traditionally, unauthorized users can remove an administration set during an ongoing infusion. Even with “free flow”
protection, this acts leads to an unwanted interruption of therapy and possible damage to the administration set. Traditionally,
the incorporation of a set-locking mechanism has added cost and complexity to the design.

 

		b.	This design provides a locking mechanism that offers minimal control complexity and cost.

 

		i.	A simple pin is spring loaded to grab a detent of an admin set while it is being loaded. It
is normally engaged. There are an endless variety of mechanisms to achieve this locking function.

 

		ii.	In order to retract the locking pin, the system retracts the pneumatic piston to its limit position, beyond the normal operation
of the piston during pumping, and engages a pin lifting lever.

 

		iii.	The motor requires no power to retain its position, so the unlocking position does not consume any incremental energy to keep
the system in a load/ unload position indefinitely.

 

    	 	6	 

     

    

  

		iv.	The design has a controllable vent feature, so the movement of the pneumatic piston, when the
vent feature is activated, does not
have any impact on the pressure of the fluid, which remains at atmospheric pressure without any opportunity for fluid flow,
since both the inlet and outlet valves are closed in this instance.

 

		v.	The movement of the pin lever to load or unload the admin set provides another useful function. This movement provides a discrete
switch function to identify the absolute position of the pneumatic piston. In this way, the
position of the piston is re-calibrated with every new admin set.

 

		c.	The locking pin offers a powerful mechanical advantage so the user is not tempted to remove the set without first turning OFF
the infusion via the pump’s user interface.

 

		d.	A purposely, but simple, procedure, using a commonly available tool to be determined, such as a
tongue depressor, a pen tip, or a Luer fittling, can be used to remove the set in an emergency.

 

		6.	“Dual Capacity Pump”: The use of separate high and low speed pneumatic drives to provide extended pressure and rate
ranges.

 

		a	Traditionally, a pump struggles with meeting a wide dynamic range. At low flow rates the motor drive moves with its smallest
resolution with increasing long dwell periods. At highest rates, the motors run at their maximum speed, but with limited torque
or drive force.

 

		b.	This design, because of the pneumatic coupling, provides a unique opportunity for multiple parallel pneumatic drives. One drive
could be geared in such a way for maximum force and a second driver could provide maximum throughput at lower pressures.

 

		7.	“Downstream Air Detection”: The detection means for air in a fluid pumping chamber by observation of volume change
required to open a downstream pressure-based flow valve.

 

		a.	Traditionally, air detection systems involve separate sensors, measurements, and interpretation algorithms. This traditional
approach suffers from significant component cost, processing complexity, and problems associated with an imbalance of sensitivity
and specificity.

 

		b.	This design exploits the fact that a post-fill cycle measurement of change-in-pressure as a function
of change-in-volume is a measurement of total air volume. The known change in volume while pumping is a fundamental benefit of
this design. The pitch of the leadscrew, combined with the precise diameter of the pneumatic piston and further combined with
the position of the piston, provides a calculation of the total gas volume. Following a fill cycle, if the measurement of
total gas volume is higher than normal, then that “error” provides a precise measurement of contained air in the system.
The nominally PSlg checkvalve provides an important period of measurement where there is no flow, so the compliance measurement
can be made with no interference of volume
chances resulting from fluid flow. This provides a very simple computation of air volume.

 

    	 	7	 

     

    

  

		i.	A measure of post-fill high compliance provides an indication of one of two conditions. Air may have entered the system from
the source. Alternatively, the fill cycle may have been incomplete, as would occur with an occluded inlet or fully evacuated non-vented
supply container.

 

		ii.	The ambiguity of the signal for high compliance can be resolved with repeated fill cycles. Ultimately, even if the problem
is unresolved, it leads to the exact same outcome- the cessation of pumping and an alarm.

 

		8.	“Upstream Air Detection”: The detection of air ingress to a pumping chamber by observation of pressure change patterns
during a FILL cycle.

 

		a.	In conventional direct drive pumps, the sensitivity to fluid ingress to the system is low. The coupling of pressure transducers
to tubing based systems is compromised. With some pneumatic systems, the air drive mechanism is not calibrated.

 

		b.	This design allows for precise measurement of pressure changes with known volume displacements. During the fill cycle, if changes-in-pressure are low relative to changes-in-volume, then that is an unambiguous indication of air entering the system. Conversely,
if the changes-in-pressure are unusually high, that is an indication of an occluded inlet. This provides additional richness of
context to the system, without requiring an additional “measurement step”, because these measurements are captured during
the normal filling cycle. This reduces the computational and operational overhead.

 

		9.	“Spill Protection Means”: The use of a pneumatic interface with a ball detent that creates a fluid tight seal for
a device when the administration set is removed.

 

		a.	Medical pumps operate in a hostile environment. Liquids of all sorts are commonly found in contact with the pump. The management
of devices due to liquid contamination is a significant cost and reliability issue for traditional designs.

 

		b.	This design uses a pneumatic connection between the device and a disposable admin set that could potentially allow ingress
of fluids inside of the pump. The design incorporates four features which reduce the chance of device contamination.

 

		i.	The pneumatic interface is horizontal and facing downward, providing the least likely angle for fluid to contact it. The air
passage is sheltered by the “roof ’ of the device.

 

		ii.	A spring loaded ball sits and fills the hole, sealing it from outside fluids, when the admin set it not loaded.

 

    	 	8	 

     

    

  

		iii.	The admin set nir passage is
designed from a grid that pushes the, ball out of the hole when the admin set is loaded in
the pump. The creates a low resistance path for air moving in and out of the pump when the admin set is installed.

 

		iv.	An 0-ring is part of each new
admin set, so the elastomeric element of the interface is freshly replaced on each use, eliminating the need for preventive maintenance
procedures.

 

		10.	“Dual High Cracking Pressure Valves”: The use
of high cracking pressure valves to serve as both a flow stop mechanism and control valve function in a fluid delivery system.

 

		a.	Traditionally, companies have provided a “flow stop” mechanism which occludes flow when an admin set is removed from
the pumping device, The flow control is binary, either on or off, and provides no function when the admin set is loaded into the
device.

 

		b.	This design incorporates a downstream spring loaded occluding element, external to a fluid pathway, which closes flow when
internal pressures exceed a nominal pressure of about 1 PSig. When the admin set is removed, it requires an external force greater
than the head height available from the set geometry to permit flow. It
therefore, achieves the purpose of a “free flow” protection system. The design further, however, provides function
while in the pump as a downstream control valve. During the fill cycle, this downstream valve closes and allows fluid to
be exclusively withdrawn into the pump chamber from the source. A benefit of the design is the economy of using this spring
mechanism for two purposes, flow stop and distal control valve. Another benefit of the design is the use of an external valving
mechanism, to avoid any issues with fluid biocompatibility.

 

		c.	The system requires an additional one-way checkvalve in series with the distal control valve. This arrangement allows flow
to the patient when the driving pressure exceeds maximum of (the outlet valve cracking pressure) AND (the patient line pressure
plus outlet checkvalve cracking pressure). So, the distal control valve cracking pressure establishes the minimum pressure under
which flow will occur.

 

		d.	The closure of the outlet control valve under low driving pressures has two critical functions.

 

		i.	If the pumping chamber is vented, the flow from the pump will
stop immediately. This makes for a reliable, rapid, and simple way to stop flow.

 

		ii.	Following each FILL cycle, there is a period of time when the pumping chamber is isolated from both the source fluid and
                                                                                                     the patient tube. This provides a useful diagnostic window, without the complications of any pressure changes due to
                                                                                                     flow.

 

    	 	9	 

     

    

  

		11.	“Inlet Source Switch”: The use of a mechanical fluid switch among inlet channels, if so configured. The switch is
purely mechanical and serves to select fluid from two or more inlet tubes. The switch position can be read electronically using
a Hall sensor or the like in order to provide context and coaching to the user.

 

		a.	Traditionally, the primary line and the “piggyback” line arc connected by a checkvalve,
restricting flow from the primary to only one direction. If
the piggyback line is sufficiently above the primary fluid level, then flow comes into the pump only from the piggyback.
If the piggyback source is lowered, then fluid will flow from the
primary into the source container of the piggyback, filling the piggyback tubing. The passive nature of the traditional valving
creates a family of operational constraints and opportunity for error. The pump is traditionally unaware of the position of the
two fluid sources and is forced to make assumptions, sometimes incorrectly, as to which fluid is being delivered. The traditional
checkvalve arrangement also precludes using a high impedance source container for the piggyback, such as a syringe. This arrangement
does offer, however, one significant operational feature in the ability to use the primary fluid to “back flush” the
piggyback line. This back flushing procedure can remove air in the
piggyback line and can reduce the opportunity for drug incompatibility leading to precipitation of other reactions in
the piggyback tubing.

 

		b.	This design, retains all of the advantages of traditional back flushing of a piggyback line, and creates a primary/ piggyback
relationship that is unconstrained by head height or containers. In other words, the source containers can, during infusion, be
at any height or have any source impedance without compromising flow performance.

 

		c.	The preferred embodiment uses a standard 3-way stopcock upstream of the pumping mechanism that can be positioned by a rotary
mechanism.

 

		i.	The inlet valves are actively controlled while in the pump. When activated, the pump can withdraw fluid specifically from either
source. Neither source configuration has any impact on the other. The pump always knows which fluid is being delivered and the
user has no opportunity for error.

 

		ii.	A certain valve position momentarily opens the two source containers together, giving the user a chance to apply higher pressure
to the primary line and move fluid into the piggyback tubing and container. The back priming does require proper procedure and
does pose a risk of improper dilution of fluids, but the risk is greatly reduced from the current procedure for piggyback programming.

 

		d.	It is obvious that an additional
mechanism and additional stopcock valve could extend the inlet switching from 2 sources to 3.

 

    	 	10	 

     

    

 

		12.	Breeze®

 

		a.	Seek registered trademark for Breeze®, using BreezeTM in the meantime.

 

		b.	A gentle air-powered pumping system that is so simple to use- it’s a Breeze®.

 

    	 	11Exhibit
10.20

 

TurnPoint
Medical Devices, Inc.

150
Allen Road, Suite 305 

Basking
Ridge, NJ 07920-2977

 

December
7, 2016

 

Mr.
Jeffrey Carlisle 

Leveraged
Developments LLC 

75
Congress Street 

Portsmouth,
NH 03801

 

Dear
Mr. Carlisle:

 

In
order to enable the completion by Leveraged Developments LLC (“LD”) of the Development Plan for the Product
provided for in the Development Agreement (“Development Agreement”) with an Effective Date of March 14, 2014
and executed October 29, 2014 between LD and TurnPoint Medical, Inc. (then known as Point Medical, Inc.)(“TPM”)
as amended on January 28, 2015, TPM and LD are entering into this letter agreement to extend from December 1, 2016 until February
15, 2017 (the “Extended Payment Term”) the period for which TPM will make payments to LD, upon the terms and
conditions set forth herein. Terms used but not defined in this letter agreement shall have the meaning ascribed to them in the
Development Agreement.

 

We
hereby agree as follows:

 

		1.	During the Extended
Payment Term, LD will work to complete the Development Plan for the Product so as to enable the filing by TPM of the 510(k) with
the FDA for the Product which we are targeting for not later than January 15, 2017. LD will work to complete the following items
to enable testing and filing as quickly as possible. Completed items to include:

		a.	Complete
engineermg specifications

		b.	Product
functionality to support claims/design inputs.

		c.	Design
transfer to production

		d.	Internal
performance test results conveyed

		e.	Internal
verification and validation of software

		f.	Production
samples suitable for 3rd party testing

 

		2.	Specifically, during
the Extended Payment Term, LD will focus on completing the Product, including software and UI, and will support the process of
preparation for 510(k) submission, including technical support and collaborative responses to requests that TPM makes for information
necessary for the 510(k) submission. TPM will contract for human factors (usability) testing and other support work not being performed
by LD.

 

		3.	During the Extended
Payment Term, LD shall provide and will support full data access to TPM for all Breeze related documents, design files and software
code, without restriction, and shall facilitate the transition of all data sources to TPM accounts.

 

     

     

    

  

		4.	During the Extended
Payment Term, LD shall engage in the following improvement projects for the Breeze product line:

		a.	Improved Cassette
Design: document and provide description and design concepts for an improved cassette. Improved cassette designs could include
improved functionality, reliability, manufacturability and lower cost.

 

		b.	Software and product
design specifications for higher volume Breeze pump, targeted above 2.0 L/hr, with proof of concept, estimates of final performance
and test documentation.

 

		c.	Research of concept
and test documentation for MRI suite use of the Breeze pump, accessory design, functional verification to the extent possible and
documentation.

 

		5.	During the Extended
Payment Term, TPM will make payments to LD for the payroll of its employees to the extent involved in the completion of the Development
Plan as follows: $80,000 per month for two months, with payments due on December 1, 2016 and on January 1, 2017, and then $40,000
on February 1, 2017. In addition, during the remainder of the Extended Payment Term, in order to recognize the LD concerns expressed
regarding operating margin, TPM will pay a margin above payroll of 10%. Specifically, this will be a payment of $8000, 15 days
after the signing of this letter agreement, and January 15, 2017, and a payment of $4000 on February 15, 2017.

 

		6.	Not later than 15
days after the signing of this letter agreement, TPM will maintain a special account, with a balance of $50,000, for the purpose
of insuring payments due LD per terms. This account will only be used in the event that TPM requires these funds to be used to
pay LD funds that are due.

 

		7.	TPM will pay for
the reasonable pre-approved charges of the contractors engaged by LD who are working on the Development Plan, consistent with past
practice, during the Extended Payment Term unless otherwise agreed by TPM. As to contractors presently working with LD, TPM will
reimburse LD for the charges which TPM has approved in its reasonable discretion, subject to the foregoing. TPM reserves the right
to contract directly with contractors who are newly engaged to work on the Development Plan. Examples include:

 

		a.	Expenses for 3rd
party technical testing of the pump and the admin sets; from entities such as Intertek, VitalMed and other possible 3rd
party test labs as approved by TPM and needed by LD/TPM will continue to be contracted by and invoiced to TPM.

 

		b.	Expenses for 3rd
party development engineering and consulting resources that are currently approved by TPM and active and engaged by LD, such as
Continuum and Pat Kelly will continue to be reimbursed to LD per current process.

 

    	 	2	 

     

    

  

		c.	The funds provided
under this Agreement will not cover technical services contracted independently by TurnPoint Medical Devices, Inc. such as CriTech
Research.

 

		d.	Leveraged Developments
will support activities related to manufacturing, but Leveraged Developments is not responsible for costs for tooling, automation,
part qualification, or production.

 

		e.	The latest approved
expenses submitted to TPM by LD have been brought to a zero balance as of this Continuation Letter.

 

		f.	TPM has named CriTech
Research as a designated contractor to assist LD in the completion of the BreezeTM software at TPM’s expense and direction.
LD has agreed to collaborate with the application of CriTech expertise and advisory in working with LD software resources to best
enable most efficient and effective software design and coding for Breeze. Consistent with our intent to apply resources in this
way, we have not approved to pay for other incremental software resources/personnel proposed by LD at this time.

 

		8.	TPM plans to negotiate
for a product support and enhancement agreement with LD, anticipated to take effect February 15, 2017, after the end of the Extended
Payment Term, which will provide for technical product support and enhancement by LD anticipated during the time that the Product
is under review at FDA and beyond. This agreement may also include development work by LD of new products, and the like. However,
nothing in this paragraph shall be deemed to require either party to enter into any such agreement.

 

		9.	TPM recognizes that
LD wishes, during this Extended Payment Term, to accelerate the pre-approval process for resources to which LD wishes to commit
and to have subsequent reimbursement by TPM. During this Extended Payment Term TPM agrees to make its best effort to respond to
LD by phone or email with questions and/or approval within 3 business hours of LD requests for resources. LD agrees to provide
with the requests a clear indication of intent/need for the resources, the costs involved and expected impact on the project.

 

		10.	The parties acknowledge
and agree that they have allocated to the Development Agreement for the completion of the Development Plan, the payments that TPM
was to make to LD for its payroll and its contractors under the Research and Development Agreement executed on October 29, 2014
as amended and that no additional payments are due to LD under such Research and Development Agreement.

 

		11.	Reference
is made to Section 4.4.2 of the Development Agreement where upon the terms set forth therein TPM granted a non-exclusive license
to LD outside of the Field subject to TPM’s right of first refusal as set forth therein. LD has requested that TPM waive
its right of first refusal under such Section 4.4.2 with respect to products outside of the Field.

 

    	 	3	 

     

    

  

In
exchange for the extension of the Restrictive Covenant Period referred to in Section 12 of this Agreement, and subject to the terms
and provisions of this letter agreement, TPM and LD agree as follows:

 

		a.	TPM agrees that
LD may grant sublicenses under the non-exclusive license granted to it under Section 4.4.2 of the Development Agreement (each an
“Outside the Field Sublicense” , subject to the provisions hereof and the Development Agreement.

 

		b.	LD and each holder
of an Outside the Field Sublicense shall indemnify, hold harmless and defend TPM, its officers, directors, employees and agents
and their respective successors and assigns from and against all expenses, costs of defense (including without limitation reasonable
attorneys’ fees), claims, losses, damages, judgements and the like relating to or arising from the Outside the Field Sublicense
or any product or service made thereunder including without limitation product liability claims, personal injury and property damage
claims, patent infringement claims, and any other claim, demand, loss or damage.

 

		c.	LD shall not
disclose any of TPM’s Confidential Information to any person with whom it discusses a potential Outside the Field Sublicense
unless such person has executed a confidentiality and non-use agreement with TPM on terms acceptable to TPM.

 

		d.	TPM will be deemed
to have waived its right of first refusal under Section 4.4.2 of the Development Agreement with respect to products specified in
any Outside the Field Sublicense which is entered into in compliance with the provisions hereof and with the Development Agreement.

 

		12.	Reference is made
to the restrictive covenants set forth in Section 8.5 of the Development Agreement which are applicable to both Jeffrey Carlisle
(who is referred to in Section 8.5 as the “Executive” and will hereafter be referred to as the “Executive”)
and to LD during the Restrictive Covenant Period (as defined in Section 8.5). In consideration of the matters set forth in this
letter agreement, including Section 11 hereof, LD and Executive agree to extend the Restrictive Covenant Period for no less than
a two-year period, and to such end, hereby amend and restate the definition of the Restrictive Covenant Period to be as follows:
the Restrictive Covenant Period shall mean the period beginning with the Effective Date and ending upon the later of (i) two years
after Regulatory Approval for the Product and (ii) May 30, 2019.

 

		13.	The parties agree
that the Development Agreement and Research and Development Agreement as amended are in full force and effect subject only to the
modifications effected by this letter agreement.

 

    	 	4	 

     

    

  

IN
WITNESS HEREOF, the undersigned, intending to be legally bound, do hereby execute this letter agreement where indicated below.

 

	Very truly
    yours,	 	 
	 	 	 
	TURNPOINT
    MEDICAL DEVICES, INC.	 	 
	 	 	 
	BY:	/s/ Jerry
    Ruddle	 	 
	 	Jerry Ruddle, President	 	 

 

	AGREED AND ACCEPTED

 LEVERAGED DEVELOPMENTS LLC	 	 
	 	 	 
	 	 	12/7/2016
	By:	/s/ Jeffrey Carlisle	 	 
	 	Jeffrey Carlisle	 	 

 

	/s/ Jeffrey Carlisle	12/7/2016	 	 

Jeffrey
Carlisle, individually, referred to as the “Executive”, as to Section 12 hereof

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]